MeSH tree: D12.776.828
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialized in mRNA technology with the goal of advancing cancer treatments.
Jun 12, 2025
0
0
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
Jun 4, 2025
0
3
US President Donald Trump's administration on Wednesday canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said.
May 29, 2025
0
0
The U.S. Food and Drug Administration (FDA) has ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines.
May 22, 2025
0
30
Trinity College Dublin researchers have found that the BNT162b2 COVID-19 vaccine may offer protection beyond its intended primary target. In a study recently published in the Clinical Immunology journal, researchers found ...
Apr 28, 2025
0
183
Sydney scientists have revealed why receiving a booster vaccine in the same arm as your first dose can generate a more effective immune response more quickly. The study, led by the Garvan Institute of Medical Research and ...
Apr 28, 2025
0
246
COVID-19 vaccination in early pregnancy (≤20 weeks of gestation) is not associated with increased prevalence of major structural birth defects, according to a study published online March 14 in Pediatrics.
Mar 14, 2025
0
0
A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.
Mar 5, 2025
0
0
President Donald Trump signed an executive order withholding funding from schools and universities that require students to be vaccinated against COVID.
Feb 18, 2025
0
0
An elderly patient in Louisiana is in "critical condition" with severe avian influenza, US authorities announced Wednesday, the first serious human case in the country as fears grow of a possible bird flu pandemic.
Dec 19, 2024
0
0
